Zanubrutinib shows sustained superior PFS ... Innovators Network Endowed Chair and an associate professor in the Clinical Research Division at Fred Hutch Cancer Center, and an associate professor ...
In clinical trials, up to 80 per cent of patients’ cancers responded to treatment with zanubrutinib, according to NHS England. The organisations said around 470 patients are set to benefit from ...
The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.
The inclusion of new entities and the deletion of outdated ones reflect ongoing research and clinical observations ... inhibitors, zanubrutinib and ibrutinib, for patients with relapsed or ...
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...
and now we have enrolled more than 1300 patients across the overall clinical trial program. At ASH, we presented the data from the phase 1 study that is a combination of zanubrutinib and sonrotoclax.
At the American Society of Hematology (ASH) Annual Meeting, held on December 7–10, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were ...
outpacing competitors such as BeiGene’s Brukinsa (zanubrutinib), Eli Lilly’s Jaypirca (pirtobrutinib), InnoCare’s Inokai (orelabrutinib), all of which remain in late-stage clinical trials ...